Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

Study identifier:H8O-CR-GWBH

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Safety and Efficacy of Exenatide Taken Before Lunch and Before Dinner Compared With Before Breakfast and Before Dinner in Patients With Type 2 Diabetes Using Oral Antidiabetic Therapy

Medical condition

Type 2 Diabetes

Phase

Phase 3

Healthy volunteers

No

Study drug

exenatide

Sex

All

Actual Enrollment

377

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Sept 2006
Primary Completion Date: 01 Jul 2007
Study Completion Date: 01 Jul 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria